The American Society of Clinical Oncology has issued its first clinical practice guideline on management of invasive cervical cancer. Among the recommendations:

• Extrafascial hysterectomy either alone or after neoadjuvant chemotherapy may be an option for stage IA1 to IVA cervical cancer when radiation therapy is not an option.

• Concurrent radiotherapy and chemotherapy is standard in enhanced and maximal settings for stage IB to IVA disease.

• When no brachytherapy is available, extrafascial hysterectomy or its modification for women who have residual tumor 2 or 3 months after concurrent chemoradiotherapy and additional boost is recommended.

• If resources are available and the patient cannot be cured, palliative radiotherapy should be used.

• Where resources are constrained, single- or short-course radiotherapy can be used with re-treatments for persistent or recurrent symptoms.

• Single-agent chemotherapy is recommended for stage IV or recurrent cervical cancer.

• Concurrent radiotherapy and chemotherapy followed by brachytherapy is standard in enhanced and maximal settings for stage IB to IVA disease.